11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

医学 曲妥珠单抗 内科学 佐剂 辅助化疗 肿瘤科 化疗 乳腺癌 癌症
作者
David Cameron,Martine J Piccart,Richard D. Gelber,Marion Jennifer Procter,Aron Goldhirsch,Evandro de Azambuja,Gilberto de Castro,Michael Untch,Ian Smith,Luca Gianni,Jose M Baselga,Nedal Jaffer Abdulla Al-Sakaff,Sabine Lauer,Eleanor T. Mcfadden,Brian R Leyland-Jones,Richard H. Bell,Mitch Dowsett,Christian Jackisch
出处
期刊:The Lancet [Elsevier BV]
卷期号:389 (10075): 1195-1205 被引量:1046
标识
DOI:10.1016/s0140-6736(16)32616-2
摘要

Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of comparing observation with two durations of trastuzumab treatment at a median follow-up of 11 years, for patients enrolled in the HERA (HERceptin Adjuvant) trial.HERA (BIG 1-01) is an international, multicentre, open-label, phase 3 randomised trial of 5102 women with HER2-positive early breast cancer, who were enrolled from hospitals in 39 countries between Dec 7, 2001, and June 20, 2005. After completion of all primary therapy (including, surgery, chemotherapy, and radiotherapy as indicated), patients were randomly assigned (1:1:1) to receive trastuzumab for 1 year (once at 8 mg/kg of bodyweight intravenously, then 6 mg/kg once every 3 weeks) or for 2 years (with the same dose schedule), or to the observation group. Primary endpoint is disease-free survival, and analyses are in the intention-to-treat population. Hazard ratios (HRs) were estimated from Cox models, and survival curves were estimated by the Kaplan-Meier method. Comparison of 2 years versus 1 year of trastuzumab is based on 366-day landmark analyses. This study is registered with ClinicalTrials.gov (NCT00045032).Of the 5102 women randomly assigned in the HERA trial, three patients had no evidence of having provided written informed consent to participate. We followed up the intention-to-treat population of 5099 patients (1697 in observation, 1702 in 1-year trastuzumab, and 1700 in 2-years trastuzumab groups). After a median follow-up of 11 years (IQR 10·09-11·53), random assignment to 1 year of trastuzumab significantly reduced the risk of a disease-free survival event (HR 0·76, 95% CI 0·68-0·86) and death (0·74, 0·64-0·86) compared with observation. 2 years of adjuvant trastuzumab did not improve disease free-survival outcomes compared with 1 year of this drug (HR 1·02, 95% CI 0·89-1·17). Estimates of 10-year disease-free survival were 63% for observation, 69% for 1 year of trastuzumab, and 69% for 2 years of trastuzumab. 884 (52%) patients assigned to the observation group selectively crossed over to receive trastuzumab. Cardiac toxicity remained low in all groups and occurred mostly during the treatment phase. The incidence of secondary cardiac endpoints was 122 (7·3%) in the 2-years trastuzumab group, 74 (4·4%) in the 1-year trastuzumab group, and 15 (0·9%) in the observation group.1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival, compared with observation. 2 years of trastuzumab had no additional benefit.F Hoffmann-La Roche (Roche).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
学阿斗发布了新的文献求助10
1秒前
wumumu发布了新的文献求助10
1秒前
2秒前
hahaha发布了新的文献求助10
2秒前
风吹麦浪的应助被有钱哥哥采纳,获得10
3秒前
3秒前
4秒前
carroline81发布了新的文献求助10
4秒前
机长发布了新的文献求助10
4秒前
瞿qks发布了新的文献求助10
4秒前
Franklin发布了新的文献求助10
6秒前
BPX完成签到,获得积分10
6秒前
安详香旋完成签到,获得积分10
7秒前
7秒前
华仔的应助被沉默采纳,获得10
8秒前
soda发布了新的文献求助10
8秒前
Lee完成签到,获得积分10
9秒前
9秒前
ZMR121121完成签到,获得积分10
10秒前
香蕉觅云的应助被rby采纳,获得10
10秒前
zs发布了新的文献求助30
10秒前
ljx123完成签到,获得积分10
10秒前
10秒前
小蘑菇的应助被马浩然采纳,获得10
10秒前
10秒前
lkw完成签到,获得积分10
10秒前
QZJ666完成签到,获得积分10
11秒前
11秒前
李健的应助被重要的映冬采纳,获得10
11秒前
上官若男的应助被再也不熬夜采纳,获得10
11秒前
大个的应助被blinkals57采纳,获得10
12秒前
闫ber完成签到 ,获得积分10
12秒前
英姑的应助被走四方采纳,获得10
15秒前
15秒前
15秒前
彪壮的语芙完成签到 ,获得积分10
15秒前
上官若男的应助被WU_JIABIN采纳,获得10
16秒前
Orange的应助被学术bug采纳,获得10
16秒前
tx的应助被Gigang采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178866
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805411
捐赠科研通 7774048
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478628